Key result
SERPINC1 promoter mutation g.2143 C>G is linked to type I antithrombin deficiency via impaired transcription.
Why the study?
Mutations affecting regulatory regions of the SERPINC1 gene with functional effects on antithrombin levels had not been identified.
Observational
This study identifies the first mutation affecting a regulatory region of the SERPINC1 gene associated with antithrombin deficiency, supporting the inclusion of the promoter region in molecular diagnostic analyses.
May guide variant interpretation in antithrombin deficiency families; extends SERPINC1 regulatory spectrum but needs confirmation before clinical adoption.
Antithrombin is the main endogenous anticoagulant. Impaired function or deficiency of this molecule significantly increases the risk of thrombosis. We studied the genetic variability of SERPINC1 , the gene encoding antithrombin, to identify mutations affecting regulatory regions with functional effect on its levels. We sequenced 15,375 bp of this gene, including the potential promoter region, in three groups of subjects: five healthy subjects with antithrombin levels in the lowest (75%) and highest (115%) ranges of our population, 14 patients with venous thrombosis and a moderate antithrombin deficiency as the single thrombophilic defect, and two families with type I antithrombin deficiency who had neither mutations affecting exons or flanking regions, nor gross gene deletions. Our study confirmed the low genetic variability of SERPINC1 , particularly in the coding region, and its minor influence in the heterogeneity of antithrombin levels. Interestingly, in one family, we identified a g.2143 C>G transversion, located 170 bp upstream from the translation initiation codon. This mutation affected one of the four regions located in the minimal promoter that have potential regulatory activity according to previous DNase footprinting protection assays. Genotype-phenotype analysis in the affected family and reporter analysis in different hepatic cell lines demonstrated that this mutation significantly impaired, although it did not abolish, the downstream transcription. Therefore, this is the first mutation affecting a regulatory region of the SERPINC1 gene associated with antithrombin deficiency. Our results strongly sustain the inclusion of the promoter region of SERPINC1 in the molecular analysis of patients with antithrombin deficiency.
No takes yet. Share an insight, caveat, or question.
Morena‐Barrio et al. (2012) conducted an observational in Antithrombin deficiency. g.2143 C>G transversion in the SERPINC1 promoter region vs. Wild-type SERPINC1 was evaluated on Functional effect on downstream transcription and antithrombin levels. A g.2143 C>G transversion in the SERPINC1 promoter region was identified in a family with type I antithrombin deficiency, significantly impairing downstream transcription.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: